QT variability during initial exposure to sotalol: Experience based on a large electronic medical record

Europace

Volumn 15, Issue 12, 2013, Pages 1791-1797

  Weeke, Peter ^a,b   Delaney, Jessica ^a   Mosley, Jonathan D ^a   Wells, Quinn ^a   Van Driest, Sara ^a,c   Norris, Kris ^a   Kucera, Gayle ^a   Stubblefield, Tanya ^a   Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arrhythmia; Atrial fibrillation; Beta blocker; Electronic medical records; Long QT syndrome; Torsades de pointes

Indexed keywords

LOOP DIURETIC AGENT; SOTALOL;

ADULT; AGE; AGED; ARTICLE; BRADYCARDIA; COMPLETE HEART BLOCK; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PALPITATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; HYPOTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; TORSADE DES POINTES; TREATMENT OUTCOME;

ARRHYTHMIA; ATRIAL FIBRILLATION; BETA-BLOCKER; ELECTRONIC MEDICAL RECORDS; LONG QT SYNDROME; TORSADES DE POINTES;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTI-ARRHYTHMIA AGENTS; ELECTRONIC HEALTH RECORDS; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; LINEAR MODELS; LOGISTIC MODELS; LONG QT SYNDROME; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; SOTALOL; TIME FACTORS; TORSADES DE POINTES;

EID: 84890493283     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut153     Document Type: Article

References (22)

1. RodenDM. LongQTsyndrome: reduced repolarization reserve and the genetic link. J Intern Med 2006;259:59-69.
2. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350: 1013-22.
3. Hondeghem LM. Thorough QT/QTc not so thorough: removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. J Cardiovasc Electrophysiol 2006;17:337-40.
4. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:651-745.
5. Chung MK, Schweikert RA, Wilkoff BL, Niebauer MJ, Pinski SL, Trohman RG et al. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 1998;32:169-76.
6. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-AndersonAet al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008;358:999-1008.
7. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003;289:2120-7.
8. Gaudron P, Kugler I, Hu K, BauerW, Eilles C, Ertl G. Time course of cardiac structural, functional and electrical changes in asymptomatic patients after myocardial infarction: their inter-relation and prognostic impact. J AmColl Cardiol 2001;38:33-40.
9. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993; 270:2590-7.
10. Choy AM, Darbar D, Dell'Orto S, Roden DM. Exaggerated QT prolongation after cardioversion of atrial fibrillation. J Am Coll Cardiol 1999;34:396-401.
11. Davey PP, Barlow C, Hart G. Prolongation of theQTinterval in heart failure occurs at low but not at high heart rates. Clin Sci (Lond) 2000;98:603-10.
12. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on Dofetilide Study Group. N Engl J Med 1999;341:857-65.
13. Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 1990;65:74A-81A; discussion 2A-3A.
14. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of nonantiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. Drug Saf 2002;25:263-86.
15. Lasser KE, Allen PD,Woolhandler SJ, Himmelstein DU,Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002;287:2215-20.
16. Yang T, RodenDM. Extracellular potassiummodulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation 1996;93: 407-11.
17. Roden DM, Yang T. Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve. Circulation 2005;112:1376-8.
18. Fiset C, Drolet B, Hamelin BA, Turgeon J. Block of IKs by the diuretic agent indapamide modulates cardiac electrophysiological effects of the class III antiarrhythmic drug dl-sotalol. J Pharmacol Exp Ther 1997;283:148-56.
19. Turgeon J, Daleau P, Bennett PB, Wiggins SS, Selby L, Roden DM. Block of IKs, the slow component of the delayed rectifier K+ current, by the diuretic agent indapamide in guinea pig myocytes. Circ Res 1994;75:879-86.
20. Kehoe RF, Zheutlin TA, Dunnington CS, Mattioni TA, Yu G, Spangenberg RB. Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. Am J Cardiol 1990;65:58A-64; discussion 5A-6A.
21. Stanton MS, Prystowsky EN, Fineberg NS, Miles WM, Zipes DP, Heger JJ. Arrhythmogenic effects of antiarrhythmic drugs: a study of 506 patients treated for ventricular tachycardia or fibrillation. J Am Coll Cardiol 1989;14:209-15; discussion 16-7.
22. Lehmann MH, Hardy S, Archibald D, quart B, MacNeil DJ. Sex difference in risk of Torsades de pointes with d,l-sotalol. Circulation 1996;94:2535-41.